1334313-75-5

Upstream product

• 1334313-65-3 (2R,5R)-2-[(chloromethyl-dimethyl-silanyl)-methyl]-5-isopropyl-3,6-dimethoxy-2,5-dihydro-pyrazine 
• 1334313-74-4 (R)-3,3-dimethyl-[1,3]azasilolidine-1,5-dicarboxylic acid 5-[2-(4-bromo-phenyl)-2-oxo-ethyl]ester 1-tert-butyl ester 
• 268224-29-9 (R)-3,3-dimethyl-[1,3]azasilolidine-1,5-dicarboxylic acid 1-tert-butyl ester 
• 268224-19-7 (2R,5R)-2-(((iodomethyl)dimethylsilyl)methyl)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine 
• 268224-27-7 (R)-1-tert-butyl-5-methyl 3,3-dimethyl-1,3-azasilolidine-1,5-dicarboxylate 

Downstream Products

• 1426838-38-1 C₂₇H₃₀ClN₃O₂Si 
• 1426836-37-4 C₄₅H₆₂N₈O₆Si 
• 1426836-38-5 C₃₅H₄₆N₈O₂Si 
• 1426836-51-2 C₄₅H₅₈N₈O₆Si 
• 1426836-67-0 C₄₁H₅₂Cl₂N₈O₆Si 
• 1426836-66-9 (R)-tert-butyl 5-(5-(4'-(2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-chloro-1H-imidazol-5-yl)biphenyl-4-yl)-4-chloro-1H-imidazol-2-yl)-3,3-dimethyl-1,3-azasilolidine-1-carboxylate 
• 1426836-68-1 C₃₈H₄₇FN₆O₄Si 
• 1426836-69-2 C₂₈H₃₁FN₆Si 
• 1426836-70-5 C₄₂H₅₃FN₈O₆Si 
• 1426836-71-6 C₄₂H₅₂ClFN₈O₆Si 
• 1426836-72-7 C₃₈H₄₈N₆O₄Si 
• 1426836-76-1 C₃₈H₄₆Cl₂N₆O₄Si 
• 1426836-77-2 C₂₈H₃₀Cl₂N₆Si 
• 1426836-87-4 C₄₀H₅₂N₆O₄Si 

Relevant academic research and scientific papers

FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

no abstract published

SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, E, F and L are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.

SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, D and R2 are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.